Meta-analysis of the impact of strut thickness on outcomes in patients with drug-eluting stents in a coronary artery
M Iantorno, MJ Lipinski, HM Garcia-Garcia… - The American Journal of …, 2018 - Elsevier
The aim of this network meta-analysis is to assess the impact of strut thickness on clinical
outcomes in patients who underwent percutaneous coronary intervention. We searched …
outcomes in patients who underwent percutaneous coronary intervention. We searched …
Coronary artery revascularization in patients with diabetes mellitus
EJ Armstrong, JC Rutledge, JH Rogers - Circulation, 2013 - Am Heart Assoc
1676 Circulation October 8, 2013 have been demonstrated in both rat23 and human studies
after angioplasty in type 2 DM. 24, 25 Increased neointimal hyperplasia in the diabetic artery …
after angioplasty in type 2 DM. 24, 25 Increased neointimal hyperplasia in the diabetic artery …
Short-and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from …
S Bangalore, S Kumar, M Fusaro, N Amoroso… - Circulation, 2012 - Am Heart Assoc
Background—Drug-eluting stents (DES) have been in clinical use for nearly a decade;
however, the relative short-and long-term efficacy and safety of DES compared with bare …
however, the relative short-and long-term efficacy and safety of DES compared with bare …
Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice …
EP Navarese, K Tandjung, B Claessen, F Andreotti… - Bmj, 2013 - bmj.com
Objectives To investigate the safety and efficacy of durable polymer drug eluting stents
(DES) and biodegradable polymer biolimus eluting stents (biolimus-ES). Design Network …
(DES) and biodegradable polymer biolimus eluting stents (biolimus-ES). Design Network …
Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patient years of follow-up …
S Bangalore, S Kumar, M Fusaro, N Amoroso… - Bmj, 2012 - bmj.com
Objectives To evaluate the efficacy and safety of currently used drug eluting stents
compared with each other and compared with bare metal stents in patients with diabetes …
compared with each other and compared with bare metal stents in patients with diabetes …
First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised …
EP Navarese, M Kowalewski, D Kandzari, A Lansky… - Open …, 2014 - openheart.bmj.com
Background First-generation drug-eluting stents (DES) have become the most widely used
devices worldwide for management of coronary artery disease. As remote follow-up data …
devices worldwide for management of coronary artery disease. As remote follow-up data …
Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III …
M Maeng, HH Tilsted, LO Jensen, LR Krusell, A Kaltoft… - The Lancet, 2014 - thelancet.com
Background In head-to-head comparisons of coronary drug-eluting stents, the primary
endpoint is traditionally assessed after 9–12 months. However, the optimum timepoint for …
endpoint is traditionally assessed after 9–12 months. However, the optimum timepoint for …
Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome
MJ Mack, AP Banning, PW Serruys, MC Morice… - The Annals of thoracic …, 2011 - Elsevier
BACKGROUND: Diabetes mellitus increases adverse outcomes after coronary
revascularization; however, the impact of metabolic syndrome is unclear. We examined the …
revascularization; however, the impact of metabolic syndrome is unclear. We examined the …
Sirolimus-coated balloon in all-comer population of coronary artery disease patients: the EASTBOURNE DIABETES prospective registry
Background The outcomes of percutaneous coronary intervention (PCI) in diabetic patients
are still suboptimal, and it is unclear if diabetic patients might derive a benefit from the use of …
are still suboptimal, and it is unclear if diabetic patients might derive a benefit from the use of …
Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent …
Objectives: This study sought to compare the safety and efficacy of the Xience V/Promus
everolimus-eluting stent (EES)(Abbott Vascular, Temecula, California) with the Endeavor …
everolimus-eluting stent (EES)(Abbott Vascular, Temecula, California) with the Endeavor …